VANDAELE PHARMA
ActiveSummary
VANDAELE PHARMA has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €320,048 and a net result of €53,941. Equity is growing by about 3.9% per year across the filed financial years. Its solvency ranks better than 35% of 12,724 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
18-03
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
31-03
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
20-03
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
21-03
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
30-09
Financial
Highest result from 2019 to 2025net €149,674 ▲80.6%
Operating result €148,008, net result €149,674, both a record.
23-03
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
23-03
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
2020
25-03
NBB filing
Annual accounts filed
financial year 2019 · micro format
2019
27-03
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
30-03
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format
2017
22-03
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 17 annual accounts filed, the latest 10 are here; all 17 are under Financials.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.